[Approach to prostate cancer in men older than 75 years: active or passive?].
Based on the exponential aging of the population and the increasing life expectancy in industrialized western countries, prostate cancer (PCa) in elderly men is becoming a disease of increasing significance. Consensus exists that men over the age of 75 years should not be screened for PCa; however, higher age as a single parameter should not exclude men from being diagnosed with prostate cancer and treated accordingly. It is well-known that overdiagnosis and overtreatment are frequent in this age group. Competing mortality risks of men older than 75 years may supersede the risk of dying from PCa several fold. Both the treating physician and the patient himself should therefore balance the possible risks and benefits of diagnosing and treating prostate cancer concerning the impact on quality of life. This is of special importance when taking into account that the complication rates of curative treatment modalities are higher in older patients than in younger men and that hormonal treatment might have negative effects especially in older men.Age, existing comorbidities, cognitive and physical status in combination with specific tumor parameters are useful tools for an individualized treatment.Therapy should be considered for healthy, active men aged 75 years or older who present with high-risk PCa and/or with a PSA doubling time <12 months. Elderly men who are unfit or have low to intermediate risk PCa will most likely not benefit from treatment.
Urologische Universitätsklinik, Inselspital Bern, Anna Seiler-Haus, CH-3010, Bern, Schweiz. martin.spahn@insel.ch
M
M
Spahn
K
K
Haeni
D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015897:Comorbidity; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D018579:Patient Selection; D015995:Prevalence; D016016:Proportional Hazards Models; D011468:Prostatectomy / Q000401:mortality* / Q000706:statistics & numerical data*; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000601:surgery*; D012307:Risk Factors; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents